Podcasts about Mariposa

This week on Black Fat Femme, we’re joined by our good sis Simone Mariposa for a powerful conversation on divine embodiment—what it means to listen to your body, mind, and spirit in a world that constantly pulls us out of alignment. We break down how to get your internal “systems” working together, where to start if you feel disconnected, and how Simone’s lived experiences shape her approach to healing and self-awareness. Plus, we talk Obama Library rollout and the Tyra Banks documentary drama while rolling our eyes, hard. We want to hear from you! Send us an email with your thoughts/comments about the show: BlackFatFemmePod@gmail.com. Also, don’t forget to watch and subscribe on YouTube! Buy DoctorJonPaul's book here! Follow the show on social: Instagram | BlueSky | Threads | Tik-Tok | Facebook Follow DoctorJonPaul: BlueSky | Instagram | Website | Tik-Tok Follow Jordan: Instagram | Website | Tik-Tok Follow Simone: Instagram | TikTok | Website See omnystudio.com/listener for privacy information.

The combined FBI and family reward for information leading to the resolution of Nancy Guthrie's disappearance exceeds one million dollars. An anonymous man who claims to know where she is buried chose not to collect it. He called Buscando Corazones Nogales — a volunteer search collective operating in Sonora, Mexico — and directed them to coordinates in the Mariposa arroyos near the Arizona border, approximately seventy miles from Guthrie's Tucson residence. He described her clothing. He described the terrain. He said dig.Volunteers searched twice based on his directions. Both searches produced no evidence connected to Guthrie. After the first failure, the caller contacted the group again with revised coordinates. A third search was subsequently scheduled. At no point did the caller contact the FBI, the Pima County Sheriff's Department, or any U.S. law enforcement agency. The Pima County Sheriff's Department confirmed it had not been contacted by Mexican authorities regarding the searches.Robin Dreeke, retired chief of the FBI's Counterintelligence Behavioral Analysis Program, examines the behavioral significance of how this tip was routed. The ransom notes that surfaced earlier in the investigation were sent to media outlets rather than law enforcement. This tip was sent to a volunteer group rather than the agencies offering the reward. Dreeke identifies the behavioral thread connecting both decisions and explains what the caller's willingness to provide revised coordinates after an initial failure reveals about the nature of the information — and the person behind it.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #NancyGuthrieMexico #GuthrieSearch #BuscandoCorazones #FBI #SavannahGuthrie #TrueCrimeToday #TrueCrime #PimaCounty #NogalesSearch

He called once. Gave coordinates. Described clothing. Fifteen volunteers searched the Mariposa arroyos near the Arizona-Mexico border and found nothing. Then he called back. New directions. A second search. Still nothing. A third search was scheduled. And through all of it, this anonymous man never contacted the FBI, never contacted Pima County, and never reached for the million-dollar-plus reward that has been sitting unclaimed since Nancy Guthrie disappeared from her Tucson home.The persistence is either the behavior of someone who genuinely knows where she is and miscalculated the exact location — or it's the behavior of someone adjusting a fabricated story in real time after each miss. Robin Dreeke has spent a career distinguishing between those two patterns. He ran the FBI's Counterintelligence Behavioral Analysis Program, and what he sees in this caller's behavior connects to every unverifiable claim this case has generated — from the ransom notes sent to media outlets to this tip sent to a volunteer collective in cartel territory.The routing alone tells a story. The ransom notes bypassed law enforcement and went to newsrooms. This tip bypassed law enforcement and went to a nonprofit search group in Sonora. Dreeke explains what that pattern means behaviorally — and why the caller's willingness to provide increasingly specific details after failed searches doesn't necessarily make the tip more credible. It may make it less. The Pima County Sheriff's Department says it hasn't been contacted by Mexican authorities. No U.S. law enforcement participated in the searches.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #NancyGuthrieMexico #GuthrieSearch #BuscandoCorazones #FBI #SavannahGuthrie #HiddenKillers #TrueCrime #PimaCounty #NogalesSearch

Before anyone picked up a shovel, the caller had already crossed a line that separates a vague tip from something investigators take seriously: he described what Nancy Guthrie was wearing. Not a guess. Specific clothing. He described landmarks in the Mariposa arroyos west of Nogales, Mexico — a stretch of desert seventy miles from her Tucson home. He gave a location precise enough for fifteen volunteers to walk to a spot and start digging. And then he provided something else: details about the terrain that only someone familiar with that ground would know.Retired FBI Counterintelligence Behavioral Analysis Program Chief Robin Dreeke breaks down what level of detail actually means in a tip like this — and why more specificity doesn't always equal more credibility. The caller described clothing, but investigators have never publicly released what Nancy was wearing when she disappeared. That means the caller either has genuine knowledge, or he built a detail specific enough to sound credible without being verifiable. Dreeke explains how the FBI stress-tests exactly that distinction.Then the behavior after the first failure. The volunteers searched and found nothing. The caller reached back out with revised directions. In Dreeke's world, that's the fork: a person correcting honest coordinates they miscalculated looks one way. A person adjusting a fabricated story after it didn't land looks another. The caller did this while walking past over a million dollars in reward money and routing the tip to a volunteer group instead of law enforcement — the same bypass pattern the ransom notes followed when they went to newsrooms instead of the FBI.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #NancyGuthrieMexico #GuthrieSearch #RobinDreeke #FBI #SavannahGuthrie #HiddenKillersLive #TrueCrime #PimaCounty #NogalesSearch

A volunteer collective in Nogales, Mexico, is actively searching for Nancy Guthrie's remains near the Arizona border — and neither the FBI nor the Pima County Sheriff's Department is involved. What happened to Nancy Guthrie may have crossed an international border, or it may be the latest false lead in a case that keeps attracting them. Either way, the people doing the digging are fifteen volunteers in cartel territory, not federal investigators.The Nancy Guthrie Mexico tip came from an anonymous caller who contacted Buscando Corazones Nogales — a group that searches for the missing in Sonora — claiming Nancy was buried in the Mariposa arroyos west of the border city. He gave a specific location, described landmarks and clothing, and told them to dig. Two searches have produced nothing. The caller reached back out after the first failure with revised directions. A third search is scheduled.This episode examines why a legitimate, experienced search group took this tip seriously enough to mobilize twice — and what the evidence says about whether they should go a third time. The location logic has a dark rationality to it. The caller's persistence could mean knowledge or could mean fabrication. The institutional silence from every federal agency could mean the tip has no weight, or it could mean something else entirely.And the national coverage missed the most important detail: those arroyos were already a graveyard. The volunteers had recovered thirty-two people from that ground before this tip ever arrived.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #SavannahGuthrie #TrueCrimeToday #NancyGuthrieMexico #GuthrieSearchGroup #NancyGuthrieMissing #GuthrieAnonymousTip #BuscandoCorazones #TrueCrime #GuthrieCaseUpdate

In February, sources indicated the FBI was in contact with Mexican law enforcement regarding the Guthrie investigation. Sonora's attorney general publicly stated no formal request had been received. Four months later, an anonymous tip directed a cross-border search for Nancy's remains near Nogales — and the Pima County Sheriff's Department says it learned about the operation from media reports.The tip was not routed through the FBI's legal attaché office in Mexico City, the suboffice in Hermosillo, or the Pima County tip line. It was directed to Buscando Corazones Nogales, a volunteer collective that conducts searches for Mexico's own missing. The group searched and found nothing connected to Nancy. The Mariposa corridor where they searched had previously yielded more than 25 unmarked graves with at least 32 sets of remains.Retired FBI Special Agent Jennifer Coffindaffer examines the procedural failures in cross-border communication, the legal framework for joint U.S.-Mexico investigative operations, and what the routing of the anonymous tip suggests about its origin and intent.Tucson is approximately sixty miles from the Nogales crossing. No public statement has addressed whether investigators have ruled out the possibility that Nancy was moved across the border.Footer Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags: #NancyGuthrie #SavannahGuthrie #MexicoBorderSearch #PimaCounty #FBI #Tucson #Nogales #JenniferCoffindaffer #TrueCrime #HiddenKillers

The anonymous caller didn't just say Nancy Guthrie was in Mexico. He described clothing. He gave landmarks. He told a volunteer search group in Nogales exactly where to dig — in the Mariposa arroyos near the Arizona border. That level of specificity is either someone who knows something or someone who wants you to believe he does.The Nancy Guthrie update that went national in June actually started a month earlier. The call came on May 10th. Buscando Corazones Nogales sent fifteen volunteers to the location on May 16th. They found nothing. The caller reached back out with revised directions. A second search on June 10th turned up nothing. A third search is scheduled. The story broke nationally when El Imparcial published and the aggregator chain followed — not because evidence was found, but because a headline was available.This episode walks through why the tip could be credible — the location logic, the persistence, the physical details — and why it might not be. The caller bypassed over a million dollars in reward money and went to a channel with no verification process. Two searches have failed. And the suspect on Nancy's porch doesn't look like someone who pre-planned a cross-border disposal.But the story underneath the headline is the one nobody's telling. The volunteers who searched for Nancy had already recovered the remains of thirty-two people from those same arroyos. No rewards offered. No national coverage. Not a single headline.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #SavannahGuthrie #HiddenKillers #NancyGuthrieMexico #GuthrieClothingTip #NancyGuthrieMissing #GuthrieFalseLeads #BuscandoCorazones #TrueCrime #GuthrieCaseUpdate

Tucson is sixty miles from the Nogales border crossing. If the person who took Nancy Guthrie had even basic knowledge of the border corridor, the window to move her across was measured in hours, not days. And four months later, investigators have not publicly stated whether they've ruled that possibility out.An anonymous caller recently directed a volunteer group in Nogales, Mexico, to an area near the Mariposa corridor where they claimed Nancy's remains were buried. The group found nothing connected to her. The Pima County Sheriff's Department says it learned about the search from media reports.Retired FBI Special Agent Jennifer Coffindaffer examines whether the proximity to the border has been adequately addressed in this investigation, what the anonymous tip's routing — to a volunteer group, not law enforcement — reveals about who may have sent it, and whether the FBI has the cross-border cooperation it needs to verify or eliminate the possibility that Nancy was taken out of the country.The search area itself tells a story: more than 25 unmarked graves containing at least 32 sets of remains were found in that same corridor during April and May searches. The ground Nancy's name was attached to is already a mass crime scene.Footer Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags: #NancyGuthrie #SavannahGuthrie #MexicoBorderSearch #PimaCounty #FBI #Tucson #Nogales #JenniferCoffindaffer #TrueCrime #HiddenKillers

It's the question nobody can answer and everybody's asking. An anonymous caller told a Mexican volunteer group that what happened to Nancy Guthrie ended in the Mariposa arroyos — a stretch of desert near the Arizona border where clandestine graves have been found before. He said her body is there. He described where to dig. The Nancy Guthrie case now stretches across an international border, and the people doing the searching are volunteers with shovels.Buscando Corazones Nogales, a collective that searches for the missing in Sonora, has conducted two searches based on this tip. Both came up empty. The caller persisted — reaching back out with revised directions after the first failure. A third search is scheduled. The Pima County Sheriff's Department says it has not been contacted by Mexican authorities. No U.S. law enforcement agency is involved.This episode lays out both sides. The location logic for burying someone in cartel territory — where remains get catalogued under a different crisis — isn't crazy. The caller's specificity is either damning or performative. The search group is legitimate and hasn't dismissed the tip. But the same questions keep surfacing: why did the caller bypass over a million dollars in rewards? Why does this tip follow the same routing pattern as the ransom notes? And why is the only response from federal law enforcement silence?The answer may be in what those volunteers already knew about that ground before this caller ever pointed them there.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #SavannahGuthrie #HiddenKillersLive #NancyGuthrieMexico #NancyGuthrieBuried #GuthrieDesertSearch #NancyGuthrieMissing #GuthrieCaseUpdate #TrueCrime #BuscandoCorazones

The Pima County Sheriff's Department says it learned about a cross-border search for Nancy Guthrie from media reports. Not from Mexican authorities. Not from the FBI's legal attaché office in Mexico City. Not from the Hermosillo suboffice. From the news.An anonymous caller reached a volunteer search collective in Nogales, Mexico, and claimed Nancy's remains were buried in the Mariposa area near the border. The group searched and found nothing connected to Nancy. But the area already held more than 25 unmarked graves with at least 32 sets of remains.Retired FBI Special Agent Jennifer Coffindaffer joins Tony Brueski and Robin Dreeke to examine what it means when the lead agency on a murder investigation discovers a cross-border development from reporters. She addresses the communication failures, whether there's a functioning investigative channel between the U.S. and Mexico on this case, and what the anonymous tip's routing says about whoever sent it.Robin Dreeke reads the behavioral implications of the sheriff's public response and what the communication breakdown reveals about the investigation's structure four months in.Footer Links:Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodDisclaimer:This publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.Hashtags: #NancyGuthrie #SavannahGuthrie #MexicoBorderSearch #PimaCounty #FBI #Tucson #Nogales #JenniferCoffindaffer #TrueCrime #HiddenKillers

Tony Brueski and Robin Dreeke apply a uniform evidentiary and behavioral standard to the three dominant theories in the Nancy Guthrie investigation: the anonymous Mexico tip, the insider-orbit theory, and the staging claim.The Mexico tip was delivered to Buscando Corazones Nogales on Mother's Day via an anonymous male caller who described clothing, landmarks, and a specific location in the Mariposa arroyos west of Nogales, Sonora. Two searches conducted by volunteers on May 16th and June 10th located no remains. The caller provided revised directions after each unsuccessful search and did not pursue over a million dollars in available reward money. The Pima County Sheriff's Department has not been contacted by Mexican authorities regarding the tip.The insider theory positions the answer within Nancy Guthrie's orbit — individuals with routine access to her property and schedule. The structural parallel to the Gail Crane case in Kentucky, in which an eighty-three-year-old was taken by a terminated caregiver sixteen days prior, is addressed. The central evidentiary challenge is the doorbell camera footage, which indicates the suspect was unaware of the recording device.The staging claim asserts the abduction was manufactured. Robin evaluates it against the absence of any documented precedent and the investigative framework for determining scene authenticity. The Guthrie family's million-dollar reward and its implications for the staging allegation are examined. Robin identifies the specific evidence that would be required for the claim to warrant formal investigative consideration.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #SavannahGuthrie #MexicoTip #InsiderTheory #StagingTheory #FBI #PimaCounty #TrueCrimeToday #Tucson #TrueCrime

Two searches of the Mariposa arroyos west of Nogales, Sonora, have been conducted based on an anonymous tip to Buscando Corazones Nogales, a volunteer collective that searches for missing persons in cartel territory. Neither search located Nancy Guthrie. A third is reportedly being planned.The anonymous caller contacted the group on Mother's Day and reported that the eighty-four-year-old was buried near a stream in a specific area of the arroyos, approximately seventy miles south of her Catalina Foothills home. He described clothing and landmarks. Fifteen volunteers searched the coordinates on May 16th and found nothing. The caller subsequently provided revised directions. A second search on June 10th also produced no results.The caller bypassed over a million dollars in combined FBI and family reward money and directed the tip to a volunteer organization rather than a law enforcement agency or established tip line. The Pima County Sheriff's Department issued a statement acknowledging awareness of the tip but confirmed it has not been contacted by Mexican authorities. The FBI has not publicly commented.Tony Brueski and Robin Dreeke examine the procedural and behavioral implications of how this information was routed — and the pattern it shares with prior unverified claims in this investigation, including ransom notes sent to media outlets and earlier reports of international leads that were never corroborated by investigating agencies.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #SavannahGuthrie #BuscandoCorazones #NogalesMexico #FBI #PimaCounty #Tucson #TrueCrimeToday #MissingPerson #TrueCrime

Retired FBI Counterintelligence Behavioral Analysis Program Chief Robin Dreeke joins Tony Brueski to decode the behavioral signature of the anonymous caller who told a Mexican volunteer group he knew where Nancy Guthrie was buried.The call came on Mother's Day. He described clothing, landmarks, a specific spot in the Mariposa arroyos near the border. Fifteen volunteers searched. Nothing. Then he called back with new directions. They searched again. Still nothing. And he walked past over a million dollars in reward money without pursuing it.Robin explains why calling back is the single most revealing behavior in this sequence. A person correcting genuine memory and a person adjusting a fabricated story after a miss produce different patterns — and Robin breaks down what to look for. The routing of this tip matches every unverifiable claim this case has generated: the ransom notes went to media, this call went to a nonprofit, and none of it went through a channel where the caller would have to identify himself.The Pima County Sheriff's Department has not been contacted by Mexican authorities. The FBI has not commented. Robin connects the behavioral thread running through the ransom notes, the Callella reports, the February international claims, and now this — and explains what a case with this much public attention does to the population of people who feel compelled to insert themselves.Join Our SubStack For AD-FREE ADVANCE EPISODES & EXTRAS!: https://hiddenkillers.substack.com/Want to comment and watch this podcast as a video? Check out our YouTube Channel. https://www.youtube.com/channel/UC8-vxmbhTxxG10sO1izODJg?sub_confirmation=1Instagram https://www.instagram.com/hiddenkillerspod/Facebook https://www.facebook.com/hiddenkillerspod/Tik-Tok https://www.tiktok.com/@hiddenkillerspodX Twitter https://x.com/TrueCrimePodThis publication contains commentary and opinion based on publicly available information. All individuals are presumed innocent until proven guilty in a court of law. Nothing published here should be taken as a statement of fact, health or legal advice.#NancyGuthrie #SavannahGuthrie #RobinDreeke #FBI #BuscandoCorazones #PimaCounty #Tucson #HiddenKillersLive #MissingPerson #TrueCrime

Le coup de coeur de Stéphanie: Mariposa

Un especial en conmemoración del Día Mundial del Medio Ambiente (5 de junio).

La lista adulta contemporánea de España top40star.es radio2050.es Segunda parte de la edición de TOP 40 STAR de 30 de mayo de 2026 @top40star

Dr. Joshua Reuss returns to the podcast to discuss the update to the living guideline on stage IV NSCLC with driver alterations. The conversation focuses on new cancer treatment strategies for patients with advanced NSCLC and EGFR mutations, including classical EGFR alterations (exon 19 deletions, exon 21 L858R substitution) and rarer alterations (exon 20 insertion mutations). Dr. Reuss discusses results from clinical trials, including MARIPOSA and CHRYSALIS-2 and how these impacted first-line and subsequent line treatment recommendations. He looks to the future on what new evidence and potential updates are in the pipeline for this living guideline. Read the full living guideline "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations, ASCO Living Guideline Version 2026.3.1"  LINK TO FULL TRANSCRIPT

El director de 'Airbag' reivindica la libertad creativa en esRadio frente a la censura ideológica y la uniformidad de las plataformas. En este episodio de esRadio, Juanma González y Dani Palacios reciben al aclamado cineasta vitoriano Juanma Bajo Ulloa en una charla que destila amor por el séptimo arte y una ácida crítica a la deriva ideológica de la industria actual. El programa arranca con una irónica reflexión sobre las subvenciones estatales al cine, evidenciando cómo el sistema imperante premia la docilidad ideológica y los perfiles normativos en detrimento del verdadero talento independiente. Este contexto sirve como marco idóneo para analizar la trayectoria de un director que siempre se ha negado a someter su visión artística a los dictados del poder político y cultural. El motivo principal del encuentro es el lanzamiento por parte de la distribuidora de las cuidadas ediciones en formato Blu-ray de sus dos primeras y laureadas películas, Alas de mariposa y La madre muerta. Bajo Ulloa defiende un cine con alma, concebido como una experiencia terapéutica y personal que busca remover los sentimientos del espectador. El realizador critica duramente la uniformidad del pensamiento único que impera en las producciones contemporáneas de plataformas de streaming como Netflix, las cuales, a su juicio, entregan productos planos y masticados que anulan la capacidad de interpretación del público a través de predecibles manuales de instrucciones morales. La conversación se detiene detalladamente en su último trabajo, El mal, una obra que ha logrado mantenerse en cartelera durante meses en salas independientes como el Pequeño Cine Estudio de Madrid gracias al boca a boca y al empeño de su autor por conectar con la audiencia. El cineasta se muestra implacable al analizar el secuestro de la cultura por parte de la corrección política y las directrices de la Agenda 2030. Denuncia que el actual cine de subvención no busca la belleza ni la catarsis, sino la propaganda y el cumplimiento de cuotas ideológicas que promueven el sectarismo y el victimismo. Esta censura sutil pero implacable ha provocado que incluso el cine familiar se vea colonizado por consignas políticas, privando a las nuevas generaciones de una fantasía en libertad y de historias que desafíen su intelecto en lugar de adormecerlo. Al rememorar el arrollador éxito de Airbag, su película más taquillera, Bajo Ulloa destapa las miserias de una industria que nunca le perdonó aquel triunfo incontestable. Revela que el proyecto pudo salir adelante al margen del sistema tradicional de financiación gracias al mecenazgo de pelotaris y cocineros vascos, lo que le garantizó una absoluta libertad creativa. La respuesta de las élites culturales y la prensa de izquierdas ante este éxito popular fue el vacío y el ninguneo, demostrando que en el panorama cultural se castiga con saña a quien se atreve a triunfar sin pasar por el aro de los comisarios políticos de turno. Fiel a su estilo, el director detalla los elementos que configuran su universo visual, caracterizado por un tono gótico y atemporal donde evita conscientemente la tecnología moderna para construir verdaderas fábulas cinematográficas. Analiza la maestría de su planificación en escenas míticas de La madre muerta, donde el suspense, el humor negro y la sordidez se entrelazan de manera magistral. Reivindica la importancia de la composición formal y el montaje frente a la desidia técnica de las realizaciones actuales, asegurando que cada plano debe poseer una función expresiva única que atrape la mirada del espectador. La entrevista concluye con una interesante comparación entre el cine de Bajo Ulloa y el aclamado cine coreano contemporáneo de directores como Park Chan-wook, creador de Oldboy, destacando la asombrosa afinidad que comparten en el uso del suspense mezclado con la tragedia y el humor salvaje. El broche de oro musical lo pone el videoclip de la canción Problemas de la mítica banda de rock Barricada, dirigido en su día por el propio Bajo Ulloa. En un emotivo tramo final, el cineasta asume con orgullo el elevado peaje de su coherencia artística, prefiriendo la marginación del sistema antes que renunciar a su libertad, recordándonos que el verdadero arte siempre será indomable y ajeno a los dictados de cualquier ingeniería social de corte estatal.

Go punch your brother before he punches you because this week we're discussing season 4, episode 17 of Lucha Underground entitled "The Moth and the Butterfly". Come along as we chat about the episode, plus peeing on TV, being stupid, dumb wrestling, fixing your man, vicious rabbits, ideal looks, trickster energy, living up to kinks, cold tags, the Jark Side, body inspiring, M.A.S.K. V The Mask, selling hard, vibrations, sibling fights, & more!Want to hear more from your favorite Marsh Land Media hosts? Hear exclusive shows, podcasts, and content by heading to Patreon.com/MLMpod!Buy some Shuffling the Deck / MLMpod MERCH, including our "Natty With Otters" shirt, over at redbubble.com/shop/msspod!Follow James @MarshLandMedia on Twitter, @MLMpod on Instagram, and listen to his music under "Marsh Land Monster" wherever music is found! Follow Sean on Twitter @SeanMarciniak and on Twitch @GooseVK! Join ourDiscord!Have fan mail, fan art, projects you want us to review, or whatever you want to send us? You can ship directly to us using "James McCollum, PO Box 180036, 2011 W Montrose Ave, Chicago, IL 60618"! Send us a voice mail to be played on the show at (224) 900-7644!Find out more about James' other podcasts "Mostly Speakin' Sentai", "Hit It & Crit It", and "This Movie's Gay" on our website,www.MLMPod.com!!! Plus, download all Marsh Land Monster albums there, too!

In this Company Update, I am joined by Roger Moss, President and CEO of Labrador Gold (TSX.V:LAB - OTCQX:NKOSF - FSE:2N6). The discussion centers on the company's recent option to acquire 100% interest in the Mariposa and Eureka Dome Projects in the Yukon's White Gold District. Roger explains the rationale behind this expansion and how it fits into the company's broader hybrid model of exploration and investment. Key Discussion Points: Yukon Asset Acquisition: Roger provides a deep dive into the Mariposa and Eureka Dome projects, detailing why these "unloved" assets in a prolific district were the perfect fit for the company's portfolio. Strategic Hybrid Model: An exploration of Labrador Gold's unique status as a hybrid explorer and investor, including the requirement to deploy $3 million in new investments by September. 2026 Exploration Plans: A look ahead at the upcoming work in the Yukon, including airborne geophysics, LiDAR surveys, and soil sampling designed to refine future drill targets. Portfolio and Cash Position: An update on the Hopedale and Watson projects, alongside a review of the company's balance sheet, which boasts over $15 million in cash.   Please email me with any questions for Roger or Ian. My email address is Fleck@kereport.com.   Click here to visit the Labrador Gold website to learn more about the Company - https://labradorgold.com/   -------------------------- For more market commentary & interview summaries, subscribe to our Substacks:  The KE Report: https://kereport.substack.com/  Shad's resource market commentary: https://excelsiorprosperity.substack.com/ Investment disclaimer: This content is for informational and educational purposes only and does not constitute investment advice, an offer, or a solicitation to buy or sell any security or investment product. Investing in equities, commodities, really everything involves risk, including the possible loss of principal. Do your own research and consult a licensed financial advisor before making any investment decisions. Guests and hosts may own shares in companies mentioned.

Si deseas recibir el podcast a diario directamente en tu celular, ingresa a Godcast.mx y date de alta gratis.

Welcome to Season 9!!! The final four of our bracket: Bob Moffitt, CJ Henderson of Smokin' Oak BBQ, Cole Sjostrom of The Alley, and Steve Aitchison of Twisted Cedar in the center court of stouts: Mariposa, CA. That's right, four award-winning, stud, number-one seeds gather on the court to take on seven…count ‘em…seven stouts as the basketball brackets go up in flames around them. God, who wrote this? If you like it, you'll want to tune into Episode 79, coming soon to a court near you.

Queridos Radioescuchas,Si nos quieren apoyar a seguir haciendo este podcast, lo pueden hacer en patreon.com/luliynabi

Jose Figueroa Garcia entrevista a Petra Klein del Jardín Mariposa a su llegada de su viaje por la Paz por 8 países europeos, un programa imperdible de Tiempos Interesantes.

Hey Dude, I took my dad back up to Yosemite after far too long an absence. It was amazing trip filled with check engine lights and giant sparks of joy.  QUOTE: "I flew up that freakin' thing!" CAST: Blayney, Jay Leno, Tom Bopp CAMEO: Ming Ming LOCATIONS: Yosemite, Oakhurst, Mariposa, Big Bear, Inland Empire, Central Valley, Yosemite Valley, Rusty's Pistons, Raley's, Chocolate Soup, Marisposa Arts, Mariposa Creek, Yosemite National Park, Wawona, Pioneer Village, South Fork of the Merced River, Curry Village, Ahwahnee Hotel, Half Dome, Tunnel View, Lower Yosemite Falls, El Capitan, Bakersfield, Grapevine, Santa Clarita, Los Angeles PROPS: Ford Ranger, Highway 99, Model T, Napa Auto, gully, NSFW SOUNDS: wind  Laguna Sawdust Cowbell Chimes  (more cowbell), birds  PHOTO: "Blayney Half Dome" shot with my iPhone XS RECORDED: May 12, 2026  in "The Cafe" under the flight path of the Hollywood Burbank Airport in Burbank, California GEAR: Zoom H1 XLR with Sennheiser MD 46 microphone. TOTAL RUNNING TIME: 23:57 FILE SIZE: ~ 23 MB GENRES: storytelling, personal storytelling, personal journal, journal, personal narrative, audio, audio blog, confessional  HYPE: "It's a beatnik kinda literary thing in a podcast cloak of darkness." Timothy Kimo Brien (cohost on Podwrecked and host of Create Art Podcast) DISCLAIMER/WARNING: Proudly presented rough, raw and ragged. Seasoned with salty language and ideas. Not for most people's taste. Please be advised.

-"Pedro Pastor" viene a nuestro programa con nuevo trabajo grande: "10 Locos Años Descalzos". En este nuevo trabajo, Pedro nos ofrece una recopilación de sus mejores temas, con nuevas colaboraciones para celebrar diez años de música. Con una producción muy cuidada el disco cuenta con las colaboraciones de Silvio Rodríguez, Chico César, Rozalén, El Kanka y El Plan de la Mariposa, entre otras. Pedro se encuentra realizando una gira por todo el país y aprovechamos, entre concierto y concierto, para hablar con él y disfrutar de este nuevo trabajo." -"Joan Piñol es psicólogo, conferenciante y experto en el ámbito del bienestar emocional. Joan Miquel Capell es jefe de Prevención y Seguridad en la Diputación de Barcelona y ha trabajado durante más de 30 años en la policía autonómica de Cataluña. Juntos nos presentan el libro "Kit de Supervivencia Emocional"-Cómo gestionar el miedo, la ira y la frustración- (Editorial Kairós)- en el que nos ofrecen herramientas valiosas para fortalecer la mente, mantener la calma en situaciones difíciles y prevenir el estrés. Concebido, en principio, para ayudar a profesionales, como médicos, policías, bomberos, cuidadores y personal de emergencias, este trabajo nos ofrece métodos eficaces y probados que nos pueden ayudar a convivir mejor con lo que se nos va presentando cotidianamente."Escuchar audio

El Ultimo de la Fila, Teddy Swims, Bob Marley, Natos y Waor, Siloé, Maki, Paula Diez, El Plan de la Mariposa y más Una nueva descarga de emociones musicales aterriza en Estación GNG con un programa cargado de estilos, recuerdos, actualidad y canciones que vuelven a demostrar por qué cada día más oyentes se unen a esta aventura musical sin etiquetas. En esta edición viajamos desde la magia eterna de El Último de la Fila y sus himnos inolvidables, hasta la potencia vocal impresionante de Teddy Swims, una de las voces más emocionantes del panorama internacional actual. También hubo tiempo para sentir la vibra inmortal de Bob Marley, cuya música sigue transmitiendo paz, conciencia y buen rollo generación tras generación. La energía urbana y las letras directas llegaron con Natos y Waor, mientras que Siloé volvió a demostrar por qué es una de las propuestas más interesantes del pop alternativo nacional. Además, disfrutamos del estilo cercano y emocional de Maki y de la sensibilidad musical de Paula Díez, en un programa donde las emociones y las historias detrás de las canciones también tuvieron protagonismo. Y como siempre en Estación GNG, seguimos descubriendo joyas musicales y artistas que aportan personalidad propia, como El Plan de la Mariposa, capaces de mezclar intensidad, poesía y sonidos diferentes dentro de una misma experiencia sonora. Pop, rock, indie, reggae, rap, sonidos alternativos y temazos del ayer y del hoy conviven cada día en un podcast musical que sigue creciendo gracias a vosotros. Más de 2 millones de descargas anuales, una comunidad espectacular y la misma filosofía de siempre: disfrutar de la música con libertad, pasión y muchísimo buen rollo. Dale al play, suscríbete, comparte el programa y únete a esta locura musical llamada Estación GNG. Paz y música.

“Quiero vivir en estado de poesía”. Con esa frase como punto de partida, Lucas Cary presentó El Mundo, el primer adelanto de su próximo disco y una canción que abre una nueva etapa en su carrera. Conversamos con el músico y compositor uruguayo sobre las búsquedas personales detrás del tema, el desafío de seguir creando en tiempos de incertidumbre y la necesidad de encontrar una voz propia dentro de la música.A dos años de Cuando estabas cerca, Lucas repasa el crecimiento artístico que atravesó entre shows, colaboraciones y escenarios compartidos con artistas como Chico César o El Plan de la Mariposa. También reflexiona sobre la humildad en la música, las relaciones y el impacto que tienen esos encuentros en su forma de escribir canciones. “Lo importante que son los vínculos humanos”, resume al recordar esas experiencias.Lucas también se detiene en las presiones de las redes sociales, el algoritmo y las dificultades de sostener una carrera artística independiente. “Quiero seguir haciendo música real, humana”, dice. Y quizás ahí esté el corazón de El Mundo: una canción sobre avanzar, incluso cuando todavía no están claras todas las respuestas.

La lista adulta contemporánea de España top40star.es radio2050.es Segunda parte de la edición de TOP 40 STAR de 2 de mayo de 2026 @top40star

En este episodio te cuento la historia de Yenisey Reyes Iturbe, una mujer que en medio de sus propios momentos de cambio descubrió el poder de vivirlos acompañada. De ese camino nació Mariposa de Fuego, un libro lleno de relatos, rituales, cantos y ceremonias para honrar cada etapa de la vida sin tener que atravesarla sola. Una historia honesta, cercana, y muy probable que en algún momento sientas que también es un poco la tuya.

On this weeks edition of The SUR Files, Joshie reflects on the 10 year anniversary of The Hoots Podcast and provides a mental health/life update from Florida. Chapter 16: The Whole Truth from Scheana Shay's Memoir. Plus, a full review of The Valley Season 3 Episode Four: Mariposa Momma, featuring a signature and raw/vulnerable fight that Kristen Doute and Luke Broderick had. The first face-to-face conversation with Danny and Jason, plus Schwartz still being a Bassit Hound. We would love to hear from you guys, comment down below your thoughts on this weeks episode of The Valley. You can follow us on TikTok @SURFiles Make sure to hit the like button and subscribe to our channel as we're on the road to 1,000 Subscribers. You can follow Joshie on X @TheHootsPodcast and Instagram @JoshLopezMusic

Efecto Mariposa celebra sus 25 años de trayectoria con 219.000 horas de vuelo, un disco en el que colaboran con grandes artistas de nuestro país para versionar los mejores hits de su carrera. De ello hablan en Cuerpos especiales, donde también indagan sobre su relación a lo largo del tiempo.

Efecto Mariposa visita Cuerpos especiales para hablar con Eva Soriano y Nacho García del disco 219.000 horas de vuelo con el que celebran 25 años de carrera. Jorge Yorya habla de la Guerra Civil de monos y Espido Freire compara Titanic con La dama y el vagabundo. Alba Cordero nos adelanta los discos que llegan el viernes 17 de abril y la Patrulla Chiquilla nos dice qué hacer para disfrutar como si estuviésemos en vacaciones.

Hallan con vida a trabajadores desaparecidosBajan homicidios en municipios del EdomexTragedia aérea en Colombia deja víctimasMás información en nuestro Podcast#grc

¿Y si te decimos que el campeonato de Venezuela en el Clásico Mundial de Béisbol frente a Estados Unidos comenzó a gestarse hace casi 70 años? Hoy en La Casa, la cabina hace un cortocircuito porque Manuel Silva, Natalia Moretti y Samuel Rodríguez reciben a nuestro profe favorito, Doriann Márquez, con el "Efecto Mariposa" más épico de la historia venezolana. Viajamos a 1958, cuando el entonces vicepresidente de EE.UU., Richard Nixon, visitó Caracas y fue recibido con todo menos cariño (literalmente le cayeron a pedradas y escupitajos). Para calmar las aguas y limpiar la imagen de los gringos, a Nixon se le ocurrió una idea brillante: enviar de gira a un equipo de Grandes Ligas para dar clínicas deportivas en Venezuela. ¡BOOM! Sembraron la semilla del deporte que hoy nos dio la mayor alegría nacional, ganándole la final en su propia cara. ¿Ironía, karma o puro guion de película?

Dr. Monty Pal and Dr. Vamsi Velcheti discuss the evolving treatment landscape in EGFR-mutated non-small cell lung cancer, including landmark trials like FLAURA2, novel drug therapies, and the growing importance of ctDNA and MRD testing. TRANSCRIPT Dr. Monty Pal: Hello, and welcome to the ASCO Daily News Podcast. I'm your host, Dr. Monty Pal. I'm a medical oncologist and professor and vice chair of academic affairs at the City of Hope Comprehensive Cancer Center in Los Angeles. Today, I'm truly delighted to introduce Dr. Vamsi Velcheti, who's a professor of medicine and the chief of hematology-oncology at the Mayo Clinic in Jacksonville, Florida. We'll be discussing the expanding treatment landscape in EGFR-positive lung cancer and how to navigate the challenges of balancing treatment efficacy, toxicity, and patient quality of life in the EGFR-positive space.  Just FYI, our full disclosures are available in the transcript of this episode.  Vamsi, it's so great to have you on the podcast. Thank you so much for being here. Dr. Vamsi Velcheti: Thank you, Monty. It's a pleasure to be here with you. It's a really exciting topic and there are a lot of updates in the EGFR space. Dr. Monty Pal: So, I'm going to need your help with this because I'll be honest with you, I see very little lung cancer, if any, in my practice. I'm pretty much exclusively kidney cancer these days. I'm coming on 20 years at City of Hope now, and I still remember when trials like ECOG 1599 were presented with, you know, platinum doublets. And, of course, the field has changed a lot since then. But tell us a little bit about the first-line landscape, and I think just for the sake of time, we're going to stick with EGFR-positive disease here. What does it look like these days? Dr. Vamsi Velcheti: Monty, the foundation of care remains the third-generation EGFR inhibitors. These are selective EGFR inhibitors, like osimertinib. We've had an evolution of the development of these TKIs. Like, you know, we had the first-generation, second-generation, not-so-selective EGFR inhibitors. Now we have mutant-selective EGFR inhibitors in the clinic, and they're doing a really good job. And these are quite effective in patients who have classical activating mutations. But the reality is that these have not been transformative. These agents have fundamentally changed the response patterns, excellent CNS penetration, and very good tolerability profile. However, we don't see a lot of durability in terms of the response. So, what's different today is now there have been several trials in combination with these third-generation EGFR inhibitors that have really laid the foundation of how we kind of think about EGFR-positive disease. At the high level, there are a lot of challenges to selecting the patients for these combination-based modalities. I'm assuming we'll be talking more about these different trials and different approaches. Some of these combination-based strategies have really moved the needle in terms of improving overall survival and really improving long-term outcomes and durability in our patients. Dr. Monty Pal: And we are going to get into the weeds on this in just a moment. But I did kick off this podcast talking about chemotherapy, ECOG 1599. It does seem as though chemotherapy is still a component of management in advanced non-small cell lung cancer. So, can you tell us about, perhaps first, you mentioned osimertinib, you know, some of these next-generation EGFR inhibitors. Tell us about the role of chemo plus osimertinib. Dr. Vamsi Velcheti: That's exactly where I was going with the combination-based strategies. You know, we first started off with our earlier trials in the EGFR space evaluating the question of, are targeted therapies, are these highly effective, third-generation, EGFR-selective inhibitors, superior to platinum-doublet chemotherapy? And we've had multiple trials demonstrating that, like the FLAURA trial and in the past with second-generation EGFR inhibitors like erlotinib and gefitinib and afatinib. So, we know that these TKIs actually perform better than platinum-doublet chemotherapy. Now, we have a large, global, phase 3 trial data from the FLAURA2 trial, which looks at the question, "Hey, you know, osimertinib is better than chemotherapy, platinum-doublet chemotherapy. Can we do even better by combining osimertinib with platinum-doublet chemotherapy?" So, FLAURA2 answered that question. This is a large, phase 3 trial, and it's a positive trial with improved durability of disease control and improving overall survival with combination with chemotherapy. So, it's a very important and landmark trial, and essentially combining osimertinib with a platinum-based chemotherapy improved responses, deepened responses, and improved overall survival and really changing the disease trajectory. And this strategy is definitely compelling, especially in patients who have certain clinical high-risk features like, you know, patients who have high disease burden or patients who are sometimes having rapid disease progression early on osimertinib, especially with patients who have a lot of visceral disease burden. So, intensifying treatments up front could alter the natural trajectory of the disease. Dr. Monty Pal: So, you sort of alluded to this in that last part there, but is that kind of how you in clinical practice select? Is it based on, you know, visceral involvement? Is it based on rapidity of disease where you think about adding chemotherapy to osimertinib? Maybe you can give us the corollary. Which patients do you just use osimertinib alone in, for instance? Dr. Vamsi Velcheti: Definitely, there are some patients who have low disease burden and they have the classical mutations, like an exon 19 deletion. And these patients, especially if they don't have a lot of disease burden, they don't have CNS involvement, there may be a subset of patients who could just do fine on osimertinib of course, with close monitoring of the disease. I guess we'll get into that later, how do we do that with either ctDNA or like closer imaging or both. So, there may be some opportunity to kind of escalate patients' treatments based on certain clinical characteristics or radiographic characteristics or certain biological characteristics informed by ctDNA or other approaches. Dr. Monty Pal: No, that's interesting. And you're right, we will chat about ctDNA in just a bit. But before we get there, I think one of the big agents that has really sort of come to the fore in advanced non-small cell lung cancer is amivantamab. I've heard a lot about this in the context of even kidney cancer because in certain subsets, I'm interested in MET-directed therapies and so forth, right? So maybe tell us a little bit about the mechanism of amivantamab first, and then maybe tell us about this pivotal MARIPOSA trial where it's combined with lazertinib. Dr. Vamsi Velcheti: So, the MARIPOSA trial compared lazertinib alone with amivantamab plus lazertinib. And this trial demonstrated overall survival advantage, and there were key differences in terms of tolerability and the safety of amivantamab, which is an EGFR and MET bispecific, and there were certain kind of unique toxicity profiles that make it a little different than the intensification approach with chemotherapy through the FLAURA2 trial. So, there's a trade-off in terms of the toxicity profile. It's a different agent and a different management protocol in terms of dermatological toxicity management that clinicians need to be comfortable with. And also, there are certain unique issues in terms of amivantamab; there's a higher rate of infusion-related reactions, there's an increased risk for edema and VTEs because of amivantamab. Certainly a different toxicity profile, different management paradigm there in terms of longitudinal care of these patients requiring dermatological care and like, you know, close monitoring and prophylaxis VTEs. But having said that, definitely it's a different strategy, and it kind of changes the biology and the natural history of the cancers, and we do see some durability of responses that we see with the MARIPOSA. So, it's certainly a great alternative, at least for some patients. Dr. Monty Pal: That was a great overview of MARIPOSA. Now comes the really difficult question, which is, how do you choose between the two? You have these two great options, right, for EGFR-positive patients. You've already highlighted some of the distinctions in terms of toxicity. I think the audience is well aware of the side effects of chemo-doublet, perhaps even the EGFR-based therapies. Amivantamab is quite new. Give us a sense of how you in clinical practice decide between the two potential options here. Dr. Vamsi Velcheti: Yeah, I think that's the big challenge. I think these are two independent strategies that have evolved through the phase 3, and both of them have demonstrated overall survival benefit. So, the way I think about this is in three dimensions, right? Like, the disease biology, the patient priorities, and feasibility of care delivery. So, when I talk about the disease biology, you know, the mechanism is very different, and MET is a very dominant driver of disease in EGFR-altered patients and it's a significant mechanism of resistance, acquired resistance to TKIs. So, certainly I think there's a patient population that could benefit from a MET-directed therapy up front. However, we don't have great data to kind of really demonstrate how using amivantamab in the front line is going to change that. And are there like perhaps like some patients who we could identify who would benefit from such a strategy? Very recently, there have been some approvals in the second-line setting in lung cancer, not in the EGFR space, but like in generally in lung cancer, with the MET ADCs, and those drugs are approved with a companion diagnostic, which requires MET IHC testing. So, what has happened, at least in large academic practices and also I think in the community now, they have been checking for MET IHC expression more routinely in lung cancer. What we have been doing in our institution is we have been doing MET IHC as a reflex for all patients with EGFR, not just EGFR, but all non-small cell lung cancer patients. What that has done is now, like, we have been increasingly testing patients with EGFR for MET. And there's clearly a subset of patients who have de novo MET expression and a high MET expression. And those patients, I've been kind of like preferentially treating them with the MARIPOSA regimen. But again, I have to caution the audience that we still don't have data that MET IHC is going to help us make those decisions, whether it's better than like a FLAURA2 regimen. But however, in the second-line setting in the CHRYSALIS trial, we know that MET is a very powerful predictor of response to amivantamab. We really need more data there, but that's what I have been doing in my practice. But also, there's a lot of patient preference here. Like, there are some patients who don't want chemotherapy, and they want a non-chemotherapy approach. So, certainly there are some patients who prefer to have amivantamab. And now with the amivantamab, the subcutaneous version, the infusion reactions and the logistics of actual administration of amivantamab are more favorable with the subcutaneous approval. So, those are some of the elements that we need to take into account. Dr. Monty Pal: Well, I want to hone in on that because this subcutaneous administration route has been a big debate that I've seen on social media. Tell us, how much easier does it actually make the amivantamab experience? Does it cut down on the rash? Is it just infusion reactions? What's been your clinical experience? Vamsi Velcheti, MD: So, the subcutaneous administration of amivantamab has definitely improved the infusion reaction issue. Very rarely patients have infusion reaction now with the subcutaneous injections. And also, the infusion time is much, much shorter. Like we don't need a lot of infusion time, which is sometimes a challenge in busy infusion clinics. We need to take that into account. As far as the impact of the subcutaneous formulation on dermatological toxicity, we haven't really seen significant difference in terms of the intensity or rates of dermatological toxicity with subcutaneous. The benefits are really with the infusion reaction, the ease of administration. And interestingly, in the PALOMA trial, it also seems to be, even though this was not the primary endpoint of the study, there seems to be some suggestion that the subcutaneous amivantamab seems to have improved OS compared to the IV amivantamab. We don't really understand why, but that's a finding from the trial that's very intriguing. Dr. Monty Pal: That is really fascinating. I'm kind of curious to see how that's going to pan out. I'm going to shift gears a little bit here. And, you know, as we sort of close, I wanted to talk a little bit about biomarkers. I mean, this is obviously not a lung cancer-specific issue. It's something we think about across the board. But what I will say is that there are certain commonalities, and in bladder cancer, we think a lot now about ctDNA. But you've been way ahead of the game in lung cancer. Tell us how you guys use ctDNA, maybe both from the standpoint of monitoring for mutational status, but if you can, maybe offer some insights into some of these new MRD tests that are available too. Dr. Vamsi Velcheti: Yeah, it's rapidly evolving. Certainly, I think in the lung cancer space, you know, this has really kicked off in the lung cancer space with incorporating ctDNA into the workflow. Of course, you know, like baseline evaluation, we still kind of heavily rely on tissue genomic sequencing. But as you know, with targeted therapy, a lot of these patients have disease that evolves over time, and changes in terms of mutational pattern driving acquired resistance is a major issue across different molecular subtypes. And especially so in EGFR, when there are certain actionable opportunities associated with that transformation. So, we need to kind of have like a longitudinal snapshot of how we monitor these patients. So, the ctDNA has come to be like a tool that has now come to the forefront of clinical workflow, and almost all my patients who are having disease progression have ctDNA for kind of evaluating for resistance and informing treatment decisions, especially in EGFR. But having said that, there are a lot of challenges in terms of using ctDNA as a tool for monitoring. There are a lot of different types of assays and different platforms, and being able to use this as a quantitative tool that would be used along with the CT scans that we routinely use in clinical practice has been a challenge. And I think I would love to hear your perspectives as well, Monty, about how you're thinking about that in bladder and other disease contexts. But having said that, I think there's a lot of opportunity to incorporate ctDNA and MRD assays into clinical decision-making. Right now, in terms of clinical trials and clinical development, there have been some very interesting trials that are currently ongoing, especially in the EGFR space. We know that patients who clear ctDNA, based on some retrospective data and also like some retrospective-prospective data from trials that have already read out, that patients who clear ctDNA early with target therapy tend to do much better. They have a longer durability of response. There may be a subset of patients who have, even though they're having radiographic response, they have persistent ctDNA after a certain time point of initiation of targeted therapy. Those patients may require escalation of therapy. We don't yet know. I can't recommend that as a standard right now because we don't have clinical evidence to support that. But however, some of the clinical trials, like the ELIOS trial that's being done right now, that's actually completed enrollment, we'll hopefully see the results very soon. So, there is an emerging thought that instead of intensifying treatment for all patients with EGFR, there may be a population that may be just fine with frontline osimertinib monotherapy and introducing the intensification strategy at the time of emergence of MRD or progression on ctDNA before radiographic progression. So, there are a lot of adaptive molecular response criteria that we are kind of exploring in clinical trials that could inform how the future is going to look like for EGFR and other perhaps targeted therapies as well. So, it's fascinating, and I think there's a lot of opportunity there. Dr. Monty Pal: You know, you asked for my perspective. I actually think that what you highlighted there is the most interesting opportunity for ctDNA: the ability to de-escalate therapy. In terms of drug development, we've done so much to bring new therapies to patients, and now it's a bit of an embarrassment of riches, but the downside is that I feel like we tend to overtreat a lot of patients in the clinic. So, I definitely view MRD, you know, some of these other ctDNA techniques with methylation and so forth that may not be sort of tumor-dependent or bespoke could be incredibly, incredibly helpful. You touched on sort of the future, right, in this last section here with biomarkers. But give us a sense now in terms of novel drug therapies in the EGFR space. What are you most excited about moving forward in 2026 and beyond? Dr. Vamsi Velcheti: Yeah, I think there's a lot going on in this space, and not just this space, but across lung cancer and others as well. Like looking at the next generation of targets for ADCs. And I think a lot of these have to do with…so far in the drug development space, as you know, the improvements in clinical outcomes has been very incremental. So, we really need to make that big leap. And I think the big leap is not going to come from, in my opinion, from the next ADC, but it's going to come from how we tailor treatments and how we monitor disease better and how do we kind of incorporate the next treatment earlier and not wait for the radiographic progression. So, there's a lot of opportunity there to integrate biomarkers and dynamic biomarkers into clinical trial design and incorporating the recent advances in terms of drug design. You know, we have a lot of assets in the EGFR space, the next-generation EGFR inhibitors that are kind of designed with resistance in mind and rational combination, knowing when to introduce those combinations is also equally important. So, there's a lot going on, really exciting times to be in drug development. The one thing that I really hope will come to the forefront in drug development, not just for lung cancer, but all disease groups, is to kind of really be thoughtful about how we incorporate these really cool molecular monitoring tools and creating a composite score with imaging to be able to like really design the next generation of clinical trials. Dr. Monty Pal: You're so spot-on with that. I definitely think that we're getting to this point where, you know, we could think about the next BiTE, the next CAR-T, the next ADC. But, you know, maybe it's time for us to start really honing in on appropriate applications of these drugs, honing in on the right dose and what have you, because I definitely see some issues there.  Vamsi, this has just been terrific. I really want to thank you so much for sharing your fantastic insights with us today on the ASCO Daily News Podcast, and I really appreciate all your efforts to move the field of lung cancer forward. Dr. Vamsi Velcheti: Thanks, Monty. I really enjoyed the conversation. Dr. Monty Pal: Yeah, this was terrific.  And thanks to our listeners as well. If you value the insights that you hear from the ASCO Daily News Podcast, please take a moment to rate, review, and subscribe wherever you get your podcasts. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. Follow today's speakers:     Dr. Monty Pal   @montypal  Dr. Vamsi Velcheti @VamsiVelcheti Follow ASCO on social media:          ASCO on X    ASCO on Bluesky         ASCO on Facebook          ASCO on LinkedIn          Disclosures:       Dr. Monty Pal:      Speakers' Bureau: MJH Life Sciences, IntrisiQ, Peerview     Research Funding (Inst.): Exelixis, Merck, Osel, Genentech, Crispr Therapeutics, Adicet Bio, ArsenalBio, Xencor, Miyarsian Pharmaceutical     Travel, Accommodations, Expenses: Crispr Therapeutics, Ipsen, Exelixis   Dr. Vamsi Velcheti:   Honoraria: Galvanize Therapeutics  Consulting or Advisory Role: Bristol-Myers Squibb, Merck, AstraZeneca/MedImmune, GSK, Amgen, Taiho Oncology, Novocure, Regeneron, Takeda, Janssen Oncology, Picture Health Research Funding (Inst.): Genentech, Trovagene, Eisai, OncoPlex Diagnostics, Alkermes, NantOmics, Genoptix, Altor BioScience, Merck, Bristol-Myers Squibb, Atreca, Heat Biologics, Leap Therapeutics, RSIP Vision, GlaxoSmithKline

Granizada paraliza Ecatepec y CoacalcoEdomex es líder en vacunación contra sarampiónIsrael frena ayuda humanitaria a GazaMás información en nuestro Podcast

CADENA 100 comenta las películas favoritas para los Oscar, como 'Una batalla tras otra' y 'Los Pecadores', cuya gala es este domingo. Se celebran elecciones en Castilla y León, con el Partido Popular como favorito sin mayoría absoluta. El ministro de Economía anuncia medidas "quirúrgicas" en lugar de rebajas de IVA o gasolina. La Junta de Andalucía financia el tratamiento de 100.000 euros mensuales para Leo, un niño con Piel de Mariposa. Mar asiste a la obra 'Constelaciones' de Sergio Peris-Mencheta, mientras Javi organiza un torneo de pádel para el cumpleaños de su hija. Jimeno y los niños critican la cocina de sus padres, y los oyentes comparten su hartazgo con juguetes ruidosos. Además, se narra la historia de Jeremiah, un padre que convierte a su hija Emily en "princesa de Sudán del Norte" al reclamar un territorio desértico. En lo musical, suenan Marc Anthony y Gente de Zona, Kygo y Ava Max, The Pretenders, Fergie y Manuel Carrasco.

El profesor Miguel del Pino hoy dedica su sección a las mariposas, en concreto a la Mariposa del Año 2026: La Pararge aegeria. ¡No te lo pierdas!

In this episode of Lung Cancer Considered, host Dr. Stephen Liu is joined by Dr. Sara Pilotto and Dr. Jonathan Riess for a virtual tumor board discussion on the management of metastatic EGFR exon 19 NSCLC . Using a complex case featuring discordant biomarker results and brain metastases, the panel explores first-line treatment strategies including osimertinib monotherapy, FLAURA2 (osimertinib plus chemotherapy), and MARIPOSA (amivantamab plus lazertinib), as well as sequencing at progression, re-biopsy, CNS considerations, and the evolving role of local consolidation and clinical trials.

En el Día Mundial de las Enfermedades Raras recogemos el testimonio de dos aragoneses que conviven con patologías poco frecuentes: la epidermólisis bullosa y la miastenia gravis. María Juárez, portavoz de la Asociación DEBRA Piel de Mariposa, nos acerca la realidad de quienes viven con piel de mariposa y las necesidades de las familias. Por su parte, José Antonio Bernad, marido de una persona con miastenia gravis, comparte cómo es el día a día con esta enfermedad y la importancia del apoyo social y sanitario.

Dr. Sonam Puri discusses the full update to the living guideline on stage IV NSCLC with driver alterations. She shares a new overarching recommendation on biomarking testing and explains the new recommendations and the supporting evidence for first-line and subsequent therapies for patients with stage IV NSCLC and driver alterations including EGFR, MET, ROS1, and HER2. Dr. Puri talks about the importance of this guideline and rapidly evolving areas of research that will impact future updates. Read the full living guideline update "Therapy for Stage IV Non-Small Cell Lung Cancer With Driver Alterations: ASCO Living Guideline, Version 2026.3.0" at www.asco.org/thoracic-cancer-guidelines TRANSCRIPT This guideline, clinical tools and resources are available at www.asco.org/thoracic-cancer-guidelines. Read the full text of the guideline and review authors' disclosures of potential conflicts of interest in the Journal of Clinical Oncology,  https://ascopubs.org/doi/10.1200/JCO-25-02822    Brittany Harvey: Hello and welcome to the ASCO Guidelines podcast, one of ASCO's podcasts delivering timely information to keep you up to date on the latest changes, challenges, and advances in oncology. You can find all the shows, including this one, at asco.org/podcasts. My name is Brittany Harvey, and today I'm interviewing Dr. Sonam Puri from Moffitt Cancer Center, co-chair on "Therapy for Stage IV Non-Small Cell Lung Cancer with Driver Alterations: ASCO Living Guideline, Version 2026.3.0." It's great to have you here today, Dr. Puri. Dr. Sonam Puri: Thanks, Brittany. Brittany Harvey: And then just before we discuss this guideline, I'd like to note that ASCO takes great care in the development of its guidelines and ensuring that the ASCO Conflict of Interest Policy is followed for each guideline. The disclosures of potential conflicts of interest for the guideline panel, including Dr. Puri, who has joined us here today, are available online with the publication of the guideline in the Journal of Clinical Oncology, which is linked in the show notes. So then, to dive into the content that we're here today to talk about, Dr. Puri, this living clinical practice guideline for systemic therapy for patients with stage IV non-small cell lung cancer with driver alterations is updated on an ongoing basis. So, what data prompted this latest update to the recommendations? Dr. Sonam Puri: So Brittany, non-small cell lung cancer is one of the fastest-moving areas in oncology right now, particularly when it comes to targeted therapy for driver alterations. New data are emerging continuously from clinical trials, regulatory approvals, real-world experience, which is exactly why these are living guidelines. The goal is to rapidly integrate important advances as they happen, rather than waiting for years for a traditional update. Since the last full update of the ASCO Stage IV Non-small Cell Lung Cancer Guideline with Driver Alterations published in 2024, there have been seven new regulatory approvals and changes in first-line therapy for some driver alterations. [This version] of the "Stage IV Non-small Cell Lung Cancer Guidelines with Driver Alterations" represents a full update, which means that the panel reviewed and refreshed every applicable section of the guideline to reflect the most current evidence across therapies including sequencing and clinical decision-making. This is to ensure that clinicians have up-to-date practical guidelines that keep pace with how quickly the field is evolving. Brittany Harvey: Absolutely. As you mentioned, this is a very fast-moving space and this full update helps condense all of those versions that the panel reviewed before into one document, along with additional approvals and new trials that you reviewed during this time period. So then, the first aspect of the guideline is there's a new overarching recommendation on biomarker testing. Could you speak a little bit to that updated recommendation? Dr. Sonam Puri: Yeah, definitely. So the panel has discussed and provided recommendations on comprehensive biomarker testing and its importance in all patients diagnosed with non-small cell lung cancer. Ideally, biomarker testing should include a broad-based next-generation sequencing panel, rather than single-gene tests, along with immunohistochemistry for important markers such as PD-L1, HER2, and MET. These results really drive treatment decisions, both in frontline settings for all patients diagnosed with non-small cell lung cancer and in subsequent line settings for patients with non-small cell lung cancer harboring certain targetable alterations. Specifically in the frontline setting, it helps determine whether a patient should receive upfront targeted therapy or immunotherapy-based approach. We now have strong data that shows that complete molecular profiling results before starting first-line therapy is associated with better overall survival and actually more cost-effective care. Using both tissue and blood-based testing can improve likelihood of getting actionable results in a timely way, and we've also provided guidance on platforms that include RNA sequencing, which are specifically helpful for identifying gene fusions that might be otherwise missed with other platforms. On the flip side, outside of a truly resource-limited setting, single-gene PCR testing really should not be routine anymore. This is what the panel recommends. It's less sensitive and inefficient and increases the risk of missing important actionable alterations. Brittany Harvey: Understood. I appreciate you reviewing that recommendation. It really helps identify critical individual factors to match the best treatment option to each individual patient. So then, following that recommendation, what are the updated recommendations on first-line therapy for patients with stage IV non-small cell lung cancer with a driver alteration? Dr. Sonam Puri: Since the last full update in 2024, there have been four additional interim updates which were published across 2024 and 2025. Compared to the last version, there have been several updates which have been included in this full update. One of the most important shifts has been in first-line treatment of patients with non-small cell lung cancer harboring the classical, or what we call as typical, EGFR mutation. The current version of the recommendation is based on the updated survival data from the phase III FLAURA2 and MARIPOSA studies, based on which the panel recommended to offer either osimertinib combined with platinum-pemetrexed chemotherapy or the combination of amivantamab plus lazertinib in the first-line treatment of classical EGFR mutations. And these recommendations, as I mentioned, are grounded in the results of the FLAURA2 and MARIPOSA trials, both of which demonstrated improvement in progression-free survival and overall survival compared to osimertinib alone in patients with common EGFR mutations. That being said, the panel actually spent significant time discussing the toxicities associated with these treatments as well. These combination approaches come with higher toxicity, longer infusion time, increased treatment frequency. So while combination therapy is now recommended as preferred, the panel has recommended that osimertinib monotherapy remains a reasonable option, particularly for patients with poor performance status and for those who are not interested in treatment intensification after knowing the risks and benefits. Brittany Harvey: Absolutely. It's important to consider both those benefits and risks of those adverse events that you mentioned to match appropriately individualized patient care. So then, beyond those recommendations for first-line therapy, what is new for second-line and subsequent therapies? Dr. Sonam Puri: So this is a section that saw several major updates, particularly again in the EGFR space. The first was an update on treatment after progression on osimertinib for patients with classical EGFR mutation. Here the panel recommends the combination of amivantamab plus chemotherapy, and this recommendation was based on the phase III MARIPOSA-2 trial, which compared amivantamab plus chemotherapy with chemotherapy alone with progression-free survival as the primary endpoint. The study met its primary endpoint, showing an improvement in median PFS with the combination of amivantamab plus chemotherapy compared to chemotherapy alone. And as expected, the combination was associated with higher toxicity. So, although the panel recommends this regimen, the panel emphasizes that patients should be counseled on the side effects which may be moderate to severe with the combination therapy approach. In addition, a new recommendation was added for patients who are not candidates for amivantamab plus chemotherapy. In those cases, platinum-based chemotherapy with or without continuation of osimertinib may be offered, and the option of continuing osimertinib with chemotherapy was recommended and supported by data from a recently presented phase III COMPEL study, which randomized 98 patients with EGFR exon 19 deletion or L858R-mutated advanced non-small cell lung cancer who had experienced no CNS progression on first-line osimertinib, and these patients were randomized to receive platinum-pemetrexed chemotherapy with osimertinib or placebo. Although this study was small, it demonstrated a PFS benefit with continuation of osimertinib with chemotherapy, and this approach may be appropriate for patients without CNS progression who prefer or require alternatives to more intensive treatment strategies. Next was an update on options for patients with EGFR-mutated lung cancer after progression on osimertinib and platinum-based chemotherapy. Here the panel recommended that for patients whose disease has progressed after both osimertinib and platinum-based chemotherapy, a new drug known as datopotamab deruxtecan can be offered as a treatment option. And this treatment recommendation was based on evaluation of pooled data from the TROPION-Lung01 and TROPION-Lung05 study, in which in the pooled analysis about 114 patients with EGFR-mutant non-small cell lung cancer were treated with Dato-DXd, 57% of whom had received three or more prior lines of treatment, and what was observed was an overall response rate of 45% with a median duration of response of 6.5 months. So definitely promising results. Next, we focused on updates to subsequent therapy options for patients with another type of EGFR mutation known as EGFR exon 20 insertion mutations. In this section, the panel added sunvozertinib as a subsequent line option after progression on platinum-based chemotherapy with or without amivantamab. Sunvozertinib is an oral, irreversible, and selective EGFR tyrosine kinase inhibitor with efficacy demonstrated in the phase II WU-KONG6 study conducted in Chinese patient population. In this study, amongst 104 patients with platinum-pretreated EGFR exon 20 mutated non-small cell lung cancer, the observed response rate was 61%. Staying in the EGFR space, the panel added a recommendation for patients with acquired MET amplification following progression on EGFR TKI therapy. In these situations, the panel recommended that treatment may be offered with osimertinib in combination with either tepotinib or savolitinib. As our listeners may know, MET amplification occurs in approximately 10% to 15% of patients with EGFR-mutated non-small cell lung cancer when they progress on third-generation EGFR TKIs, and detection of MET amplification is done with various methods, such as tissue-based methods like FISH, NGS, and IHC, as well as ctDNA-based NGS with variable cut-offs. Over the last few years, several studies have informed this recommendation. I'm going to be discussing some of them. In the phase II ORCHARD trial, 32 patients with MET-amplified non-small cell lung cancer after progression on first-line osimertinib were evaluated, where the combination of osimertinib plus savolitinib achieved an overall response rate of 47% with a duration of response of 14.5 months. More recently, the phase II SAVANNAH trial reported outcomes in 80 patients with MET-amplified tumors after progression on osimertinib, and in this patient population, the combination of savolitinib and osimertinib achieved an overall response rate of 56% with a median PFS of 7.4 months. And lastly, the phase II single-arm INSIGHT 2 trial assessed the efficacy of osimertinib plus tepotinib in patients with advanced EGFR-mutant non-small cell lung cancer who had disease progression following first-line osimertinib therapy. And in this study, in a cohort of 98 patients with MET-amplified tumors confirmed by central testing, the overall response rate with the combination was 50% with a duration of response of 8.5 months. So definitely informing this guideline recommendation. Next, we had an update on recommendation in patients with ROS1-rearranged non-small cell lung cancer. For patients with ROS1-rearranged non-small cell lung cancer, the panel recommended specifically for patients who progressed after first-line ROS1 TKIs, the addition of taletrectinib as a new option alongside repotrectinib. And this recommendation was based on analysis of the results of the TRUST-I and TRUST-II studies, which showed that amongst 113 tyrosine kinase inhibitor-pretreated patients, taletrectinib achieved a confirmed overall response rate of 55.8% with a median duration of response of 16.6 months and a median PFS of 9.7 months, a very promising agent. Finally, for patients with HER2 exon 20 mutated non-small cell lung cancer, the panel added two new oral HER2 tyrosine kinase inhibitors, zongertinib and sevabertinib, as options in addition to T-DXd and after exposure to T-DXd. These recommendations are based on early phase data from two trials: the phase I Beamion LUNG-01 study, which evaluated zongertinib, and the phase I/II SOHO-01 study that evaluated sevabertinib. In this study, zongertinib demonstrated an overall response rate of 71% in previously treated patients, with an overall response rate of 48% amongst patients who had received prior HER2-directed ADCs including T-DXd. Sevabertinib in its early phase study showed an overall response rate of 64% in previously treated but HER2 therapy-naive patients, and an overall response rate of 38% in patients previously exposed to HER2-directed therapy. The panel believes that both agents had manageable toxicity profile and represent meaningful new options for this patient population. Brittany Harvey: Certainly, it's an active space of research, and I appreciate you reviewing the evidence underpinning all of these recommendations for our listeners. So, it's great to have these new options for patients in the later-line settings. And given all of these updates in both the first and the later-line settings, what should clinicians know as they implement this latest living guideline update, and how do these changes impact patients with non-small cell lung cancer? Dr. Sonam Puri: Some great questions, Brittany. I think for clinicians when implementing this update, I think about two practical steps. First is reiterating the importance of comprehensive biomarker testing. That is the only way to identify key drivers and resistance mechanisms that we are now targeting. And second, picking a first-line strategy that balances efficacy and toxicity and patient preference for your specific patient. I think informed decision-making, shared decision-making is more important than any time right now. It has always been important, but definitely very important now. For patients, this guideline brings recommendations on more personalized treatment options for both first-line and post-progression settings, which potentially means better outcomes. But it is also very important for our patients to continue to have informed conversations about side effects, time commitment, and what matters most to them with their providers. The panel in this version of the guideline specifically acknowledges the real-world barriers that prevent patients from receiving guideline-concordant therapy, including challenges with access to comprehensive molecular testing and treatment availability, and the panel emphasizes on the importance of shared decision-making, and we provide practical discussion points to help clinicians navigate these conversations with the patient. In addition, the panel has also addressed common real-world clinical complexities, such as treating elderly or frail patients, managing multiple chronic conditions, considerations around pregnancy and fertility, and certain disease scenarios such as oligoprogression or oligometastatic disease. And where available, the guideline summarizes this existing data to support informed individual decision-making in these complex situations. Brittany Harvey: Shared decision-making is really paramount, especially with all of the options and weighing the risks and benefits and considering the individual circumstances of each patient that comes before a clinician. We've talked a lot about all of the new studies that the panel has reviewed, but what other studies or areas of research is the panel examining for future updates to this living guideline as it continues to be updated on an ongoing basis? Dr. Sonam Puri: Yes, definitely, so much to look forward to, right? Looking ahead, the panel is closely monitoring several rapidly evolving areas that are likely to shape future updates of the guideline. This includes emerging data from ongoing later-phase studies, particularly the studies that are evaluating these new targeted agents moving to earlier lines of therapy, alongside studies evaluating additional combination strategies or more refined approaches to treatment sequencing. We're also closely watching advances in biomarker testing, the evolving understanding of resistance mechanisms, development of new targets, and promising therapeutic agents. I think ultimately the living guideline exists to help clinicians and patients navigate this rapidly evolving field, and we would like to ensure that scientific advances are rapidly translated into better, more personalized patient care. Brittany Harvey: Definitely. We'll look forward to those updates from those ongoing trials and future areas of research that you mentioned to provide better options for patients with non-small cell lung cancer and a driver alteration. So I want to thank you so much for your work to rapidly and continuously update this guideline, and thank you for your time today, Dr. Puri. Dr. Sonam Puri: Thanks so much. Thanks so much for the opportunity. Brittany Harvey: And finally, thank you to all of our listeners for tuning in to the ASCO Guidelines podcast. To read the full guideline, go to www.asco.org/thoracic-cancer-guidelines. You can also find many of our guidelines and interactive resources in the free ASCO Guidelines app available in the Apple App Store or the Google Play Store. There's also a companion episode with Dr. Reuss on the related living guideline on stage IV non-small cell lung cancer without driver alterations that listeners can find in their feeds as well. And if you've enjoyed what you've heard today, please rate and review the podcast and be sure to subscribe so you never miss an episode. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.  

Luis Herrero entrevista a Lidia Osorio, madre de Leo.

“ElectroRecicla” recolecta toneladas de residuos electrónicos CDMX activa Alerta Amarilla por frío en Milpa Alta y TlalpanMariposa monarca en peligroMás información en nuestro Podcast

Mateo plants seeds in his grandmother's tiny corner of the garden and discovers that his laughter can make things grow, even after a mistake that makes his heart heavy. This is a story about a boy learning to bring joy back to himself and to the plants he loves.Want the full transcript, English translation, and vocabulary list?Become a member of our Patreon community and turn every episode into a full Spanish learning experience.Have a story you'd love to hear on the podcast? We'd love to read it! Email us at hello@spanishstoriesforkids.com=============Mateo planta semillas en el pequeño rincón del jardín de su abuela y descubre que su risa puede hacer que las cosas crezcan, incluso después de un error que le pesa en el corazón. Es la historia de un niño que aprende a devolver la alegría a sí mismo y a las plantas que cuida.¿Quieres la transcripción completa, la traducción al inglés y la lista de vocabulario? Hazte miembro de nuestra comunidad en Patreon y transforma cada episodio en una experiencia completa para aprender español.¿Tienes una historia que te gustaría que leamos? ¡Nos encantará compartirla! Escríbenos a hello@spanishstoriesforkids.com

 In tiny community of Mariposa, an excursion on the Mariposa Belle steamboat is the hottest ticket in town. What could go wrong? Stephen Leacock, today on The Classic Tales Podcast.   Welcome to this VINTAGE episode of The Classic Tales Podcast. Thank you for listening.     Let's talk about ads. Now, most podcasts offer a subscription where you can pay $10 or so a month, and you get to listen to their show with no ads, and get a few bonus episodes. Here's the thing – this largely goes to benefit the podcast platforms. The actual creators don't get much.   So, I created a better plan. For $9.99 per month, you get unlimited downloadable and streamable access to the entire Classic Tales Library. I've been building this for 18 years. This gives you access to longer books that wouldn't work in the podcast format. Books like Nicholas Nickleby, Moby Dick, or The Hunchback of Notre Dame. Only about a quarter of the books in the library were released through the podcast. So you can instantly download and listen to whatever you want, all the time. This is the Audiobook Library Card.    Go to audiobooklibrarycard.com or follow the link in the show notes, and download and listen all you want.   Go to audiobooklibrarycard.com or follow the link in the show notes.     And now, The Marine Excursion of the Knights of Pythias, by Stephen Leacock      Follow this link to get The Audiobook Library Card for $9.99/month       Follow this link to subscribe to our YouTube Channel:       Follow this link to subscribe to the Arsène Lupin Podcast:     Follow this link to follow us on Instagram:     Follow this link to follow us on Facebook:

Episode 1779 - brought to you by our incredible sponsors: Poncho - If you've been looking for the perfect shirt—something breathable, fits great, feels even better, and stands out in a good way—give Poncho a try.  Go to www.ponchooutdoors.com/hardfactor for $10 off your first order. Lucy - Let's level up your nicotine routine with Lucy.  Go to ⁠⁠Lucy.co/HARDFACTOR⁠⁠ and use promo code (HARDFACTOR) to get 20% off your first order. Lucy has a 30-day refund policy if you change your mind. Brooklyn Bedding -  Go to brooklynbedding.com and use code HARDFACTOR at checkout to get 30% off sitewide. This offer is not available anywhere else.   DaftKings - Download the DraftKings Casino app, sign up with code HARDFACTOR, and spin your favorite slots! The Crown is Yours - Gambling problem? Call one eight hundred GAMBLER 00:00:00 Timestamps 00:05:10 Serial butt sniffer arrested AGAIN!!  00:13:45 New Chiefs sideline correspondent is HOTT  00:22:40 Mariposa, CA, DA was buying Meth for 8 years and God knows what else 00:27:55 The Florida Board of Education will no longer hand out certificates to students with disabilities who could not earn the diploma, but tried really hard 00:29:50 President Trump wants to send the National Guard to Chicago 00:34:25 French marine park is jerking off its male Orca so it doesn't try to have sex with his own mother Thank you for listening!! Go to ⁠patreon.com/hardfactor⁠ to join our community. We love you, and most importantly HAGFD! Learn more about your ad choices. Visit megaphone.fm/adchoices

This is part one of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

This is part two of a two-part recapBen is out for the week, so Ronnie invites the hysterical and on point Lara Schoenhals (@larzmari) for SUP (sexyuniquepod) to talk all things The Valley. This week, Mariposa enacts her revenge plan on Jason and Janet and Lala shows up to tell Jesse what a piece of crap he is. For those of you into violins, they play again this week for poor, poor Jax who sends in a video message telling us how much he loves his son before he wrecks his and his mothers finances. You can watch this recap on video, listen to our 3 part Road Trip bonus episodes, and participate in live episode threads at patreon.com/watchwhatcrappens. Tickets for our North American tour on sale at watchwhatcrappens.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.